Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical Summit

Agentic AI the focus of innovation in Japan’s rapidly growing clinical research landscape

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced that its CEO and co-founder, Dr. Michelle Longmire, will be one of three international guest speakers at Japan’s largest pharmaceutical conference, Ubie Pharma Summit (May 13-14, 2026). Longmire will be speaking at the fifth annual event along with Justin Chen, MD, Clinical Specialist at Google for Health, and John Halamka, MD, President of Mayo Clinic Platform.

More than 1,000 attendees gathered at the Ubie Summit 2025. This year, guests include many distinguished leaders from government and medical organizations in Japan as well as global pharmaceutical organizations such as AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly Japan, GlaxoSmithKline, Novartis, Regeneron, and more.

Japan is actively strengthening its drug development landscape to eliminate drug lag and loss, aiming for ¥3 trillion ($20+ billion) in annual R&D investment by 2030 through government- private partnerships and AI, biotech, and new modality investments. Key efforts include the Sakigake fast-track designation, conditional early approvals for rare diseases, and utilizing real-world evidence (RWE).

“It is an honor to represent my company and country at Japan’s preeminent industry event,” said Medable’s Longmire. “Japan not only has a beautiful landscape but also a culture focused on innovation and modernization through advanced technology, which is exactly what we aim to bring to Japanese clinical studies with our agentic clinical development platform.”

Medable's Agent Studio transforms clinical operations capacity by tackling the repetitive, compliance-driven work that slows trials down. Instead of teams manually sorting, checking, and filing tens of thousands of documents, AI agents handle these tasks automatically, validating against study context and requirements, with human-in-the-loop oversight. Medable’s AI agents are compatible with standard clinical systems, and maintain full transparency with audit trails – delivering an AI operational layer that removes workflow bottlenecks. For example, Medable's Clinical Monitoring and TMF Agents are two enterprise-grade agents that help study teams increase efficiency.

Medable executives are also speaking at various other key life sciences industry events this month including Fierce Biotech Week in Boston (May 12-14); Scope X at Bio-IT World Expo in Boston (May 18-19); Clinical Trials Technology Congress in London (May 19-20); and, American Society of Clinical Oncology (ASCO) Conference in Chicago (May 29-June 2).

About Medable

Medable is on a mission to get effective therapies to people faster. Its agentic digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Leader in eCOA by Everest Group, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.com.